Genetic determinants of plasma lipoproteins.

Genetic determinants of plasma lipoproteins. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Genetic determinants of plasma lipoproteins. Abstract Text:

Rebecca L Pollex,Robert A Hegele,Rebecca L Pollex,Robert A Hegele,

The search for common genetic determinants of plasma lipoproteins began in the early 1980s. Despite some exceptions, these efforts have not yet yielded a set of biological markers that can be used in clinical practice. By contrast, successes in defining the molecular basis of rare single-gene disorders, such as familial hypoalphalipoproteinemia, have shown the value of experimental designs that focus on genomic analysis of individuals within the tails of Gaussian distributions of quantitative lipoprotein traits. For example, this strategy showed that a small but relevant proportion of individuals within the <5% tail of plasma HDL-cholesterol distribution have mutations in genes that cause familial hypoalphalipoproteinemia. The value of clinical testing for genomic variants as an adjunct to a biochemical measurement of plasma lipoproteins, however, is at best questionable. A more direct impact of genetic studies is that definitions of 'common' and 'large genetic effects' have become more tempered, reflecting perhaps the biological reality that plasma lipoproteins are probably determined by the aggregate of numerous modest and occasional large genetic effects in addition to environmental factors. Here, we review recent progress on genomic variants and cholesterol metabolism, and discuss the impact these genetic studies will have on clinical cardiology.

Genetic determinants of plasma lipoproteins. Publishing Authors By Initials

RL Pollex,RA Hegele,RL Pollex,RA Hegele,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Genetic determinants of plasma lipoproteins. Journal Published:

PUBLICATION TYPE: Review

Journal: Nature clinical practice. Cardiovascular medicine

VOLUME: 4

Page Numbers: 600-9

Journal Abbreviation:

ISSN: 1743-4300

DAY: 24

MONTH: Nov

YEAR: 2007

Genetic determinants of plasma lipoproteins. Information

Number of References: 73

LANGUAGE: eng

NlmUniqueID: 101226507

Genetic determinants of plasma lipoproteins. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Genetic determinants of plasma lipoproteins. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Genetic determinants of plasma lipoproteins.

AFFILIATION: Blackburn Cardiovascular Genetics Laboratory, Robarts Research Institute, Room 406, 100 Perth Drive, London, ON N6A 5K8, Canada.

Country: England

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Nat Clin Pract Cardiovasc Med

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Genetic determinants of plasma lipoproteins Related Publications

• A Glimpse at HDL-based Therapy for Atherosclerosis.
• Abetalipoproteinemia: two case reports and literature review.
• Adaptation to visuomotor rotations in younger and older adults.
• Association between the -455T>C promoter polymorphism of the APOC3 gene and the metabolic syndrome in a multi-ethnic sample.
• Association between the FTO rs9939609 polymorphism and the metabolic syndrome in a non-Caucasian multi-ethnic sample.
• Clinical and genetic associations with hypertriglyceridemic waist in a Canadian aboriginal population.
• Common variants APOC3, APOA5, APOE and PON1 are associated with variation in plasma lipoprotein traits in Greenlanders.
• Effect of change in posture and exercise on repolarization in patients with long QT syndrome with HERG channel mutations.
• Efficacy and safety of pioglitazone in treatment of a patient with an atypical partial lipodystrophy syndrome.
• Emerging antidyslipidemic drugs.
• GCK and HNF1A mutations in Canadian families with maturity onset diabetes of the young (MODY).
• Gene-environment interactions in atherosclerosis.
• Gene-environment interactions in atherosclerosis: animal models.
• Genetic determinants of plasma lipoproteins.
• Genetics of metabolic syndrome.
• Genetics of metabolic syndrome: is there a role for phenomics?
• HIV-associated dyslipidaemia: pathogenesis and treatment.
• Heterozygous CAV1 frameshift mutations (MIM 601047) in patients with atypical partial lipodystrophy and hypertriglyceridemia.
• Human hepatocyte nuclear factor-1 beta (HNF1B) 1968A/G polymorphism.
• Is raising HDL a futile strategy for atheroprotection?
• Lipoprotein (a): an emerging risk factor for atherosclerosis.
• Lipoprotein(a) and apolipoproteins B and A-I after acute myocardial infarction.
• Lipoprotein(a) and fibrinolysis.
• Lipoprotein(a): biochemistry and genetics.
• Microsomal triglyceride transfer protein inhibition-friend or foe?
• Monogenic pediatric dyslipidemias: Classification, genetics and clinical spectrum.
• Phenomics, lamin A/C, and metabolic disease.
• Single nucleotide polymorphisms of the fukutin gene.
• Spectrum of HNF1A and GCK mutations in Canadian families with maturity-onset diabetes of the young (MODY).
• The failure of torcetrapib: what have we learned?